Trials of a new drug combination to treat tuberculosis could cut the length of time patients have to take their medicine by a third.
Researchers at St George’s, University of London, hope that speeding up the treatment will help to reduce the 20 million cases of the disease that exist globally – many caused by patients abandoning their medication halfway through because of the long trek to a treatment centre or at the first signs it is working.
In the four-year trial, a high dose of antibiotic drug rifapentine and a broad-spectrum antibiotic, called moxifloxacin, will be given once a week to patients with pulmonary TB in Mozambique, Zambia, Zimbabwe and South Africa. Both rifapentine and moxifloxacin are already used in the treatment of TB, though not in combination. It is hoped that RIFAQUIN, as the new combination is called, will cut the treatment time from six to four months.
Dr. Stanley Mungofa, the Head of the Harare City Health Department, Harare, Zimbabwe, and an investigator in the RIFAQUIN trial, said: “TB treatment just like treatment for chronic diseases tends to be difficult for both the patient and the health system given the fact that when patients feel better they confuse better for cure and abandon their treatment.
“If treatment becomes shorter there is a better chance of them finishing their medication and being cured.”
The trial will start in July 2007and is being carried out by INTERTB, an international consortium of scientists coordinated by Dr Amina Jindani at St George’s, University of London. Professor Denis Mitchison, who successfully pioneered the reduction of treatment from 18 to six months, and Dr Tom Harrison are also on the St George’s INTERTB team.
Dr Jindani said: ‘The development of a new anti-tuberculosis drug could take 15 years and the cost estimated by the Stop TB partnership is almost 5 billion US dollars. By testing a new combination of drugs we already use we can cut that development time by 10 years at a far lower cost.’
The trial has already attracted grants of €4,281,991 (£2.855million) from the European & Developing Countries Clinical Trials Partnership (EDCTP) and a further £200,000 from the Wellcome Trust.
INTERTB is organising a one-day meeting to discuss the contribution of UK researchers to reduce TB treatment duration. The meeting will be held at St. George’s, University of London, on Thursday 22nd March, 2007 and will be attended by researchers in the United Kingdom as well as donor agencies, NGOs and members of the All Party Parliamentary Working Group on TB.
Tamsin Starr | alfa
Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital
New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong
Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...
An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications
Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...
Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.
The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
11.12.2017 | Physics and Astronomy
11.12.2017 | Earth Sciences
11.12.2017 | Information Technology